GM Allotypes and COVID-19. A Pilot Study Performed on Sicilian Patients.
ADCC
COVID-19
Immune response
Immunogenetics
γ marker
Journal
Translational medicine @ UniSa
ISSN: 2239-9747
Titre abrégé: Transl Med UniSa
Pays: Italy
ID NLM: 101588308
Informations de publication
Date de publication:
2022
2022
Historique:
received:
09
12
2022
accepted:
21
12
2022
medline:
21
7
2023
pubmed:
21
7
2023
entrez:
21
7
2023
Statut:
epublish
Résumé
Several studies suggest that genetic variants that influence the onset, maintenance and resolution of the immune response might be fundamental in predicting the evolution of COVID-19. In the present paper, we analysed the distribution of GM allotypes (the genetic markers of immunoglobulin γ chains) in symptomatic and asymptomatic COVID-19 patients and in healthy controls, all born and residing in Sicily. Indeed, the role played by GM allotypes in immune responses and infection control is well known. Our findings show that the GM23 allotype is significantly reduced in healthy controls. Interestingly, in a previous study, Sicilians carrying the GM23 allotype were associated with the risk of developing a symptomatic Human Cytomegalovirus infection. However, a note of caution should be considered, due to the small sample size of patients and controls.
Identifiants
pubmed: 37476201
doi: 10.37825/2239-9747.1039
pii: tlj-24-02-026
pmc: PMC10354864
doi:
Types de publication
Journal Article
Langues
eng
Pagination
26-29Informations de copyright
© 2022 Università di Salerno.
Déclaration de conflit d'intérêts
Conflict of interest No conflict of interest.
Références
Exp Clin Immunogenet. 1991;8(2):88-95
pubmed: 1789994
Immunology. 2020 Feb;159(2):178-182
pubmed: 31613998
Indian J Psychol Med. 2013 Apr;35(2):121-6
pubmed: 24049221
J Alzheimers Dis. 2019;70(3):917-924
pubmed: 31306125
Clin Immunol. 2013 Dec;149(3):475-86
pubmed: 24239836
Malar J. 2009 Dec 22;8:306
pubmed: 20028548
Int J Mol Sci. 2022 Dec 07;23(24):
pubmed: 36555106
Immun Ageing. 2018 Nov 6;15:25
pubmed: 30450118
Immunogenetics. 2018 Jan;70(1):67-72
pubmed: 28936707
J Immunol. 2015 Aug 15;195(4):1676-84
pubmed: 26179905
Front Cell Dev Biol. 2021 Sep 14;9:725606
pubmed: 34595175
Blood. 2009 Apr 16;113(16):3716-25
pubmed: 19018092
J Virol. 2004 May;78(9):4561-5
pubmed: 15078937
Front Immunol. 2019 Oct 03;10:2237
pubmed: 31632391
Immunol Rev. 2015 Nov;268(1):6-24
pubmed: 26497510
Cancer Epidemiol Biomarkers Prev. 2013 Nov;22(11):1927-30
pubmed: 24008491
Clin Immunol. 2022 Mar;236:108954
pubmed: 35149195
Immunology. 2018 Apr;153(4):523-531
pubmed: 29067686
BMJ. 1998 Apr 18;316(7139):1236-8
pubmed: 9553006
Int J Mol Sci. 2021 Mar 05;22(5):
pubmed: 33807915
Hum Immunol. 2008 Mar;69(3):158-64
pubmed: 18396207
Front Immunol. 2020 Aug 18;11:2016
pubmed: 32973808
J Infect Dis. 2008 Nov 1;198(9):1334-6
pubmed: 18855559